{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:31:07Z","timestamp":1794317467899,"version":"4.9.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fabry disease (FD) is a rare, X-linked, progressive multi-system disorder of glycosphingolipid metabolism that causes cellular and organ damage in multiple body systems. FD has not been studied as extensively in females as in males due to greater heterogeneity of presentation and variability of disease course in females. Furthermore, despite published evidence to the contrary, females are still often referred to as carriers of FD and their symptoms assumed to be mild. Findings from recent studies and patient registries show that over two-thirds of females with FD experience signs and symptoms in different body systems, with over a third experiencing severe clinical manifestations. Symptoms include a wide variety of cardiovascular, neurologic, kidney, gastrointestinal, and psychiatric\/psychologic effects, which significantly impair health-related quality of life and shorten life expectancy in affected females. Accurate and timely diagnosis is hindered by overlap of signs and symptoms (which may be non-specific) with other conditions, as well as lack of physician awareness. Females with FD are often compared with their affected male counterparts as opposed to unaffected females in the general population, which may result in less rigorous management for females than may be appropriate were they not being contrasted with males. It is more clinically appropriate to consider onset and severity of symptoms in females with FD in comparison to their unaffected counterparts in the general population. There is, therefore, a need for greater representation of females in clinical studies that are designed and powered to specifically detect endpoints in this group, and to evaluate these endpoints against those seen in females in the general population without FD. Improvements in the understanding of disease phenotypes, biomarkers, presentation, course, and outcomes in pediatric and adult females are needed.<\/jats:p>","DOI":"10.1186\/s13023-025-03922-x","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T17:35:52Z","timestamp":1755106552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Fabry disease in females: organ involvement and clinical outcomes compared with the general population"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0770-5516","authenticated-orcid":false,"given":"Robert J.","family":"Hopkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Laney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"3922_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"key":"3922_CR2","doi-asserted-by":"crossref","unstructured":"Izhar R, Borriello M, La Russa A, Di Paola R, De A, Capasso G, et al. Fabry disease in women: genetic basis, available biomarkers, and clinical manifestations. Genes (Basel) 2023;15.","DOI":"10.3390\/genes15010037"},{"key":"3922_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93:112\u201328.","journal-title":"Mol Genet Metab"},{"key":"3922_CR4","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, et al. Characterization of classical and nonclassical fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28:1631\u201341.","journal-title":"J Am Soc Nephrol"},{"key":"3922_CR5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38:769\u201375.","journal-title":"J Med Genet"},{"key":"3922_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123:416\u201327.","journal-title":"Mol Genet Metab"},{"key":"3922_CR7","doi-asserted-by":"crossref","unstructured":"Madi S, Huma F, Ahmad M, Singleton C, G. WD, Wallace E. Kidney biopsy findings in fabry females with normal serum creatinine levels (C-13). 7th update on fabry disease: biomarkers, progression and treatment opportunities in 2022. Nephron 2022;146(suppl 1):1\u201351.","DOI":"10.1159\/000524933"},{"key":"3922_CR8","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, et al. Characterization of fabry disease in 352 pediatric patients in the fabry registry. Pediatr Res. 2008;64:550\u20135.","journal-title":"Pediatr Res"},{"key":"3922_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009;11:790\u20136.","journal-title":"Genet Med"},{"key":"3922_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s10545-007-0708-6","volume":"30","author":"AL Cole","year":"2007","unstructured":"Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH. Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis. 2007;30:943\u201351.","journal-title":"J Inherit Metab Dis"},{"key":"3922_CR11","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/jimd.12271","volume":"43","author":"S K\u00f6rver","year":"2020","unstructured":"K\u00f6rver S, Geurtsen GJ, Hollak CEM, van Schaik IN, Longo MGF, Lima MR, et al. Cognitive functioning and depressive symptoms in Fabry disease: a follow-up study. J Inherit Metab Dis. 2020;43:1070\u201381.","journal-title":"J Inherit Metab Dis"},{"key":"3922_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/jmg.2005.036327","volume":"43","author":"PB Deegan","year":"2006","unstructured":"Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet. 2006;43:347\u201352.","journal-title":"J Med Genet"},{"key":"3922_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1148\/radiol.2019191385","volume":"294","author":"K Hanneman","year":"2020","unstructured":"Hanneman K, Karur GR, Wasim S, Wald RM, Iwanochko RM, Morel CF. Left ventricular hypertrophy and late gadolinium enhancement at cardiac MRI are associated with adverse cardiac events in fabry disease. Radiology. 2020;294:42\u20139.","journal-title":"Radiology"},{"key":"3922_CR14","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1007\/s12325-019-01061-x","volume":"36","author":"O Morand","year":"2019","unstructured":"Morand O, Johnson J, Walter J, Atkinson L, Kline G, Frey A, et al. Symptoms and quality of life in patients with fabry disease: results from an International Patient Survey. Adv Ther. 2019;36:2866\u201380.","journal-title":"Adv Ther"},{"key":"3922_CR15","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24:2102\u201311.","journal-title":"Nephrol Dial Transplant"},{"key":"3922_CR16","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","volume":"40","author":"K Sims","year":"2009","unstructured":"Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke. 2009;40:788\u201394.","journal-title":"Stroke"},{"key":"3922_CR17","first-page":"45","volume":"38","author":"WR Wilcox","year":"2018","unstructured":"Wilcox WR, Feldt-Rasmussen U, Martins AM, Ortiz A, Lemay RM, Jovanovic A, et al. Improvement of Fabry disease-related gastrointestinal symptoms in a significant proportion of female patients treated with agalsidase beta: data from the fabry registry. JIMD Rep. 2018;38:45\u201351.","journal-title":"JIMD Rep"},{"key":"3922_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89:44\u201354.","journal-title":"Clin Genet"},{"key":"3922_CR19","volume":"21","author":"M Beck","year":"2019","unstructured":"Beck M, Cox TM. Comment: Why are females with Fabry disease affected? Mol Genet Metab Rep. 2019;21: 100529.","journal-title":"Mol Genet Metab Rep"},{"key":"3922_CR20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","volume":"110","author":"C Chimenti","year":"2004","unstructured":"Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004;110:1047\u201353.","journal-title":"Circulation"},{"key":"3922_CR21","doi-asserted-by":"crossref","unstructured":"Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236\u201342.","DOI":"10.1111\/j.1365-2362.2004.01309.x"},{"key":"3922_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1399-0004.2011.01718.x","volume":"81","author":"O Lidove","year":"2012","unstructured":"Lidove O, Kaminsky P, Hachulla E, Leguy-Seguin V, Lavigne C, Marie I, et al. Fabry disease \u201cThe New Great Imposter\u201d: results of the French Observatoire in Internal Medicine Departments (FIMeD). Clin Genet. 2012;81:571\u20137.","journal-title":"Clin Genet"},{"key":"3922_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/gim.2014.120","volume":"17","author":"DA Laney","year":"2015","unstructured":"Laney DA, Peck DS, Atherton AM, Manwaring LP, Christensen KM, Shankar SP, et al. Fabry disease in infancy and early childhood: a systematic literature review. Genet Med. 2015;17:323\u201330.","journal-title":"Genet Med"},{"key":"3922_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2024.101891","volume":"2","author":"DA Laney","year":"2024","unstructured":"Laney DA, Houde MF, Foley AL, Peck DS, Atherton AM, Manwaring LP, et al. Prospective characterization of early symptom onset and progression in young pediatric patients with variants in the G LA gene across 5 years: Longitudinal data from the Fabry MOPPet Study. Genet Med Open. 2024;2: 101891.","journal-title":"Genet Med Open"},{"key":"3922_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107603","volume":"139","author":"C Wanner","year":"2023","unstructured":"Wanner C, Ortiz A, Wilcox WR, Hopkin RJ, Johnson J, Ponce E, et al. Global reach of over 20 years of experience in the patient-centered Fabry Registry: advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community. Mol Genet Metab. 2023;139: 107603.","journal-title":"Mol Genet Metab"},{"key":"3922_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.medcli.2018.10.039","volume":"153","author":"M Barba-Romero","year":"2019","unstructured":"Barba-Romero M, Serena J, Puig JM, Valverde CV, Climent V, Herrero JA, et al. Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy. Med Clin (Barc). 2019;153:47\u201355.","journal-title":"Med Clin (Barc)"},{"issue":"4","key":"3922_CR27","first-page":"414","volume":"62","author":"A Murs\u0103","year":"2024","unstructured":"Murs\u0103 A, Militaru S, Rusu E, Onciul S, Neculae G, Adam R, et al. Fabry disease phenotyping in women from the complete Romanian cohort-time for early diagnostic awareness. Rom J Intern Med. 2024;62(4):414\u201329.","journal-title":"Rom J Intern Med."},{"key":"3922_CR28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.21037\/cdt-20-981","volume":"11","author":"CE Kurschat","year":"2021","unstructured":"Kurschat CE. Fabry disease-what cardiologists can learn from the nephrologist: a narrative review. Cardiovasc Diagn Ther. 2021;11:672\u201382.","journal-title":"Cardiovasc Diagn Ther"},{"key":"3922_CR29","doi-asserted-by":"crossref","unstructured":"Tomioka D, Kato K, Ozawa T, Kodama K, Takahashi H, Dochi K, et al. Diverse phenotypic expression associated with the same genetic variant in female heterozygote patients of Anderson-Fabry disease: a case series. Eur Heart J Case Rep. 2021;5:ytaa538.","DOI":"10.1093\/ehjcr\/ytaa538"},{"key":"3922_CR30","doi-asserted-by":"crossref","unstructured":"Azevedo O, Gago MF, Miltenberger-Miltenyi G, Robles AR, Costa MA, Pereira O, et al. Natural history of the late-onset phenotype of Fabry disease due to the p.F113L mutation. Mol Genet Metab Rep. 2020;22:100565.","DOI":"10.1016\/j.ymgmr.2020.100565"},{"key":"3922_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","volume":"91","author":"R Schiffmann","year":"2017","unstructured":"Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int. 2017;91:284\u201393.","journal-title":"Kidney Int"},{"key":"3922_CR32","volume":"14","author":"Q Alitter","year":"2022","unstructured":"Alitter Q. Late-onset Fabry disease affecting the kidneys and liver while sparing the heart: a case report. Cureus. 2022;14: e30989.","journal-title":"Cureus"},{"key":"3922_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.2029","volume":"10","author":"L Wagenh\u00e4user","year":"2022","unstructured":"Wagenh\u00e4user L, Rickert V, Sommer C, Wanner C, Nordbeck P, Rost S, \u00dc\u00e7eyler N. X-chromosomal inactivation patterns in women with Fabry disease. Mol Genet Genomic Med. 2022;10: e2029.","journal-title":"Mol Genet Genomic Med"},{"key":"3922_CR34","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3390\/ijms21041258","volume":"21","author":"F D'Avanzo","year":"2020","unstructured":"D\u2019Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment. Int J Mol Sci. 2020;21:1258.","journal-title":"Int J Mol Sci"},{"key":"3922_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1750-1172-5-14","volume":"5","author":"LL Pinto","year":"2010","unstructured":"Pinto LL, Vieira TA, Giugliani R, Schwartz IV. Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review. Orphanet J Rare Dis. 2010;5:14.","journal-title":"Orphanet J Rare Dis"},{"key":"3922_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ymgme.2014.11.005","volume":"114","author":"M Fuller","year":"2015","unstructured":"Fuller M, Mellett N, Hein LK, Brooks DA, Meikle PJ. Absence of \u03b1-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts. Mol Genet Metab. 2015;114:268\u201373.","journal-title":"Mol Genet Metab"},{"key":"3922_CR37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1146\/annurev-med-050311-163340","volume":"64","author":"J Reiser","year":"2013","unstructured":"Reiser J, Sever S. Podocyte biology and pathogenesis of kidney disease. Annu Rev Med. 2013;64:357\u201366.","journal-title":"Annu Rev Med"},{"key":"3922_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112188","volume":"9","author":"M Mauer","year":"2014","unstructured":"Mauer M, Glynn E, Svarstad E, T\u00f8ndel C, Gubler MC, West M, et al. Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. PLoS ONE. 2014;9: e112188.","journal-title":"PLoS ONE"},{"key":"3922_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.kint.2022.03.023","volume":"102","author":"B Najafian","year":"2022","unstructured":"Najafian B, Silvestroni A, Sokolovskiy A, T\u00f8ndel C, Svarstad E, Obrisca B, et al. A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease. Kidney Int. 2022;102:173\u201382.","journal-title":"Kidney Int"},{"key":"3922_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/cge.14102","volume":"101","author":"DP Germain","year":"2022","unstructured":"Germain DP, Levade T, Hachulla E, Knebelmann B, Lacombe D, Seguin VL, et al. Challenging the traditional approach for interpreting genetic variants: Lessons from Fabry disease. Clin Genet. 2022;101:390\u2013402.","journal-title":"Clin Genet"},{"key":"3922_CR41","doi-asserted-by":"publisher","first-page":"232640981668573","DOI":"10.1177\/2326409816685735","volume":"5","author":"MA Curiati","year":"2017","unstructured":"Curiati MA, Aranda CS, Kyosen SO, Varela P, Pereira VG, D\u2019Almeida V, et al. The challenge of diagnosis and indication for treatment in Fabry disease. J Inborn Errors Metab Screen. 2017;5:2326409816685735.","journal-title":"J Inborn Errors Metab Screen"},{"key":"3922_CR42","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","volume":"84","author":"S Gupta","year":"2005","unstructured":"Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore). 2005;84:261\u20138.","journal-title":"Medicine (Baltimore)"},{"key":"3922_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","volume":"123","author":"A Nowak","year":"2018","unstructured":"Nowak A, Mechtler TP, Hornemann T, Gawinecka J, Theswet E, Hilz MJ, Kasper DC. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab. 2018;123:148\u201353.","journal-title":"Mol Genet Metab"},{"key":"3922_CR44","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","volume":"52","author":"BE Smid","year":"2015","unstructured":"Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, Hollak CE, Poorthuis BJ. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease. J Med Genet. 2015;52:262\u20138.","journal-title":"J Med Genet"},{"key":"3922_CR45","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/jmedgenet-2020-107338","volume":"59","author":"A Nowak","year":"2022","unstructured":"Nowak A, Beuschlein F, Sivasubramaniam V, Kasper D, Warnock DG. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease. J Med Genet. 2022;59:287\u201393.","journal-title":"J Med Genet"},{"key":"3922_CR46","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.2215\/CJN.0000000000000239","volume":"18","author":"SJ van der Veen","year":"2023","unstructured":"van der Veen SJ, Sayed ME, Hollak CEM, Brands MM, Snelder CKS, Boekholdt SM, et al. Early risk stratification for natural disease course in Fabry patients using plasma globotriaosylsphingosine levels. Clin J Am Soc Nephrol. 2023;18:1272\u201382.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3922_CR47","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.2215\/CJN.04340510","volume":"5","author":"C Wanner","year":"2010","unstructured":"Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol. 2010;5:2220\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3922_CR48","doi-asserted-by":"crossref","unstructured":"Arias E, Tejada-Vera B, Kochanek KD, Ahmad F. Provisional Life Expectancy Estimates for 2021. 2022.https:\/\/www.cdc.gov\/nchs\/data\/vsrr\/vsrr023.pdf. Accessed June 2024.","DOI":"10.15620\/cdc:118999"},{"key":"3922_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fcvm.2016.00007","volume":"3","author":"M Namdar","year":"2016","unstructured":"Namdar M. Electrocardiographic changes and arrhythmia in Fabry disease. Front Cardiovasc Med. 2016;3:7.","journal-title":"Front Cardiovasc Med"},{"key":"3922_CR50","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1750-1172-8-116","volume":"8","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Sanchez-Ni\u00f1o MD, Politei J, Oliveira JP, Wanner C, Warnock DG, Ortiz A. Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis. 2013;8:116.","journal-title":"Orphanet J Rare Dis"},{"key":"3922_CR51","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.ultrasmedbio.2008.10.010","volume":"35","author":"F Weidemann","year":"2009","unstructured":"Weidemann F, Strotmann JM, Niemann M, Herrmann S, Wilke M, Beer M, et al. Heart valve involvement in Fabry cardiomyopathy. Ultrasound Med Biol. 2009;35:730\u20135.","journal-title":"Ultrasound Med Biol"},{"key":"3922_CR52","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.amjcard.2017.04.016","volume":"120","author":"HC Wilson","year":"2017","unstructured":"Wilson HC, Hopkin RJ, Madueme PC, Czosek RJ, Bailey LA, Taylor MD, Jefferies JL. Arrhythmia and clinical cardiac findings in children with Anderson-Fabry disease. Am J Cardiol. 2017;120:251\u20135.","journal-title":"Am J Cardiol"},{"key":"3922_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12968-019-0557-0","volume":"21","author":"S Mathur","year":"2019","unstructured":"Mathur S, Dreisbach JG, Karur GR, Iwanochko RM, Morel CF, Wasim S, et al. Loss of base-to-apex circumferential strain gradient assessed by cardiovascular magnetic resonance in Fabry disease: relationship to T1 mapping, late gadolinium enhancement and hypertrophy. J Cardiovasc Magn Reson. 2019;21:45.","journal-title":"J Cardiovasc Magn Reson"},{"key":"3922_CR54","first-page":"883","volume":"33","author":"H Yogasundaram","year":"2017","unstructured":"Yogasundaram H, Kim D, Oudit O, Thompson RB, Weidemann F, Oudit GY. Clinical features, diagnosis, and management of patients with Anderson-Fabry cardiomyopathy. Can J Cardiol. 2017;33:883\u201397.","journal-title":"Can J Cardiol"},{"key":"3922_CR55","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.009430","volume":"12","author":"S Nordin","year":"2019","unstructured":"Nordin S, Kozor R, Vijapurapu R, Augusto JB, Knott KD, Captur G, et al. Myocardial storage, inflammation, and cardiac phenotype in Fabry disease after one year of enzyme replacement therapy. Circ Cardiovasc Imaging. 2019;12: e009430.","journal-title":"Circ Cardiovasc Imaging"},{"key":"3922_CR56","doi-asserted-by":"crossref","unstructured":"Germain DP, Brand E, Burlina A, Cecchi F, Garman SC, Kempf J, et al. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry Registry study. Mol Genet Genomic Med. 2018;6:492\u2013503.","DOI":"10.1002\/mgg3.389"},{"key":"3922_CR57","first-page":"107","volume":"22","author":"HC Liu","year":"2015","unstructured":"Liu HC, Perrin A, Hsu TR, Yang CF, Lin HY, Yu WC, Niu DM. Age at first cardiac symptoms in Fabry disease: association with a Chinese hotspot Fabry mutation (IVS4+919G>A), classical fabry mutations, and sex in a Taiwanese population from the Fabry Outcome Survey (FOS). JIMD Rep. 2015;22:107\u201313.","journal-title":"JIMD Rep"},{"key":"3922_CR58","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3390\/jcm10102160","volume":"10","author":"Y Fan","year":"2021","unstructured":"Fan Y, Chan TN, Chow JTY, Kam KKH, Chi WK, Chan JYS, et al. High prevalence of late-onset fabry cardiomyopathy in a cohort of 499 non-selective patients with left ventricular hypertrophy: The Asian Fabry cardiomyopathy high-risk screening study (ASIAN-FAME). J Clin Med. 2021;10:2160.","journal-title":"J Clin Med"},{"key":"3922_CR59","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13023-022-02599-w","volume":"18","author":"R S\u00e1nchez","year":"2023","unstructured":"S\u00e1nchez R, Ripoll-Vera T, L\u00f3pez-Mendoza M, de Juan-Ribera J, Gimeno JR, Hermida \u00c1, et al. The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants. Orphanet J Rare Dis. 2023;18:8.","journal-title":"Orphanet J Rare Dis"},{"key":"3922_CR60","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1136\/heartjnl-2020-317922","volume":"107","author":"M El Sayed","year":"2021","unstructured":"El Sayed M, Hirsch A, Boekholdt M, van Dussen L, Datema M, Hollak C, Langeveld M. Influence of sex and phenotype on cardiac outcomes in patients with Fabry disease. Heart. 2021;107:1889\u201397.","journal-title":"Heart"},{"key":"3922_CR61","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1161\/01.STR.0000230607.07928.17","volume":"37","author":"K Lakshminarayan","year":"2006","unstructured":"Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002). Stroke. 2006;37:1969\u201374.","journal-title":"Stroke"},{"key":"3922_CR62","doi-asserted-by":"crossref","unstructured":"Dresing TJ, Wikoff BL. Bradyarrhythmias. Curr Treat Options Cardiovasc Med. 2001;3:291\u20138.","DOI":"10.1007\/s11936-001-0091-9"},{"key":"3922_CR63","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1445-5994.2008.01669.x","volume":"38","author":"T Lobo","year":"2008","unstructured":"Lobo T, Morgan J, Bjorksten A, Nicholls K, Grigg L, Centra E, Becker G. Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement. Intern Med J. 2008;38:407\u201314.","journal-title":"Intern Med J"},{"key":"3922_CR64","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370\u20135.","journal-title":"JAMA"},{"key":"3922_CR65","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","volume":"28","author":"A Linhart","year":"2007","unstructured":"Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007;28:1228\u201335.","journal-title":"Eur Heart J"},{"key":"3922_CR66","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","volume":"40","author":"C Kampmann","year":"2002","unstructured":"Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M, et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol. 2002;40:1668\u201374.","journal-title":"J Am Coll Cardiol"},{"key":"3922_CR67","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/euhj.1998.1314","volume":"20","author":"H Schirmer","year":"1999","unstructured":"Schirmer H, Lunde P, Rasmussen K. Prevalence of left ventricular hypertrophy in a general population. The Troms\u00f8 Study Eur Heart J. 1999;20:429\u201338.","journal-title":"The Troms\u00f8 Study Eur Heart J"},{"key":"3922_CR68","doi-asserted-by":"publisher","first-page":"f153","DOI":"10.1093\/europace\/eux261","volume":"20","author":"S Baig","year":"2018","unstructured":"Baig S, Edward NC, Kotecha D, Liu B, Nordin S, Kozor R, et al. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. Europace. 2018;20:f153\u201361.","journal-title":"Europace"},{"key":"3922_CR69","first-page":"337","volume":"37","author":"CL Hung","year":"2021","unstructured":"Hung CL, Wu YW, Lin CC, Lai CH, Jyh-Ming Juang J, Chao TH, et al. 2021 TSOC expert consensus on the clinical features, diagnosis, and clinical management of cardiac manifestations of Fabry Disease. Acta Cardiol Sin. 2021;37:337\u201354.","journal-title":"Acta Cardiol Sin"},{"key":"3922_CR70","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","volume":"4","author":"M Niemann","year":"2011","unstructured":"Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011;4:592\u2013601.","journal-title":"JACC Cardiovasc Imaging"},{"key":"3922_CR71","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","volume":"68","author":"TR Hsu","year":"2016","unstructured":"Hsu TR, Hung SC, Chang FP, Yu WC, Sung SH, Hsu CL, et al. Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation. J Am Coll Cardiol. 2016;68:2554\u201363.","journal-title":"J Am Coll Cardiol"},{"key":"3922_CR72","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.tcm.2017.01.011","volume":"27","author":"M Disertori","year":"2017","unstructured":"Disertori M, Mas\u00e8 M, Ravelli F. Myocardial fibrosis predicts ventricular tachyarrhythmias. Trends Cardiovasc Med. 2017;27:363\u201372.","journal-title":"Trends Cardiovasc Med"},{"key":"3922_CR73","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jacc.2022.06.022","volume":"80","author":"C Orsborne","year":"2022","unstructured":"Orsborne C, Bradley J, Bonnett LJ, Pleva LA, Naish JH, Clark DG, et al. Validated model for prediction of adverse cardiac outcome in patients with Fabry disease. J Am Coll Cardiol. 2022;80:982\u201394.","journal-title":"J Am Coll Cardiol"},{"key":"3922_CR74","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.echo.2024.04.010","volume":"37","author":"HC Chang","year":"2024","unstructured":"Chang HC, Kuo L, Sung SH, Niu DM, Yu WC. Prognostic implications of left ventricular hypertrophy and mechanical function in Fabry disease: a longitudinal cohort study. J Am Soc Echocardiogr. 2024;37:787\u201396.","journal-title":"J Am Soc Echocardiogr"},{"key":"3922_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091757","volume":"9","author":"A Feustel","year":"2014","unstructured":"Feustel A, Hahn A, Schneider C, Sieweke N, Franzen W, G\u00fcnd\u00fcz D, et al. Continuous cardiac troponin I release in Fabry disease. PLoS ONE. 2014;9: e91757.","journal-title":"PLoS ONE"},{"key":"3922_CR76","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ymgme.2011.06.021","volume":"104","author":"M Torralba-Cabeza","year":"2011","unstructured":"Torralba-Cabeza M, Olivera S, Hughes DA, Pastores GM, Mateo RN, P\u00e9rez-Calvo JI. Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease. Mol Genet Metab. 2011;104:301\u20137.","journal-title":"Mol Genet Metab"},{"key":"3922_CR77","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.010171","volume":"13","author":"JB Augusto","year":"2020","unstructured":"Augusto JB, Nordin S, Vijapurapu R, Baig S, Bulluck H, Castelletti S, et al. Myocardial edema, myocyte injury, and disease severity in Fabry disease. Circ Cardiovasc Imaging. 2020;13: e010171.","journal-title":"Circ Cardiovasc Imaging"},{"key":"3922_CR78","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/ajmg.a.40369","volume":"176","author":"AW Powell","year":"2018","unstructured":"Powell AW, Jefferies JL, Hopkin RJ, Mays WA, Goa Z, Chin C. Cardiopulmonary fitness assessment on maximal and submaximal exercise testing in patients with Fabry disease. Am J Med Genet A. 2018;176:1852\u20137.","journal-title":"Am J Med Genet A"},{"key":"3922_CR79","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","volume":"9","author":"RY Wang","year":"2007","unstructured":"Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med. 2007;9:34\u201345.","journal-title":"Genet Med"},{"key":"3922_CR80","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmg.2008.065904","volume":"46","author":"A Mehta","year":"2009","unstructured":"Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G. Natural course of Fabry disease: changing pattern of causes of death in FOS\u2014Fabry Outcome Survey. J Med Genet. 2009;46:548\u201352.","journal-title":"J Med Genet"},{"key":"3922_CR81","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/acr.22752","volume":"68","author":"JA Sparks","year":"2016","unstructured":"Sparks JA, Chang SC, Liao KP, Lu B, Fine AR, Solomon DH, et al. Rheumatoid arthritis and mortality among women during 36 years of prospective follow-up: results from the Nurses\u2019 Health Study. Arthritis Care Res (Hoboken). 2016;68:753\u201362.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3922_CR82","unstructured":"Centers for Disease Control and Prevention. Leading Causes of Death\u2212Females\u2014All races and origins\u2014United States, 2017. Accessed: https:\/\/www.cdc.gov\/women\/lcod\/2017\/all-races-origins\/index.htm. 2017.https:\/\/www.cdc.gov\/women\/lcod\/2017\/all-races-origins\/index.htm. Accessed July 2022."},{"key":"3922_CR83","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","volume":"147","author":"CW Tsao","year":"2023","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147:e93\u2013621.","journal-title":"Circulation"},{"key":"3922_CR84","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","volume":"143","author":"SS Virani","year":"2021","unstructured":"Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics\u20142021 update. Circulation. 2021;143:e254\u2013743.","journal-title":"Circulation"},{"key":"3922_CR85","unstructured":"American Heart Association. 2021 Heart Disease & Stroke Statistical Update Fact Sheet Females & Cardiovascular Diseases. 2021.https:\/\/www.heart.org\/-\/media\/phd-files-2\/science-news\/2\/2021-heart-and-stroke-stat-update\/2021_stat_update_factsheet_females_and_cvd.pdf?la=en. Accessed June 2024."},{"key":"3922_CR86","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139:e56\u2013528.","journal-title":"Circulation"},{"key":"3922_CR87","first-page":"732","volume":"29","author":"H Clausen","year":"2012","unstructured":"Clausen H, Theophilos T, Jackno K, Babl FE. Paediatric arrhythmias in the emergency department. Emerg Med. 2012;29:732\u20137.","journal-title":"Emerg Med"},{"key":"3922_CR88","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.118.006273","volume":"11","author":"S Khurshid","year":"2018","unstructured":"Khurshid S, Choi SH, Weng LC, Wang EY, Trinquart L, Benjamin EJ, et al. Frequency of cardiac rhythm abnormalities in a half million adults. Circ Arrhythm Electrophysiol. 2018;11: e006273.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"3922_CR89","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/cns.12542","volume":"22","author":"JM Politei","year":"2016","unstructured":"Politei JM, Bouhassira D, Germain DP, Goizet C, Guerrero-Sola A, Hilz MJ, et al. Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther. 2016;22:568\u201376.","journal-title":"CNS Neurosci Ther"},{"key":"3922_CR90","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","volume":"46","author":"E Kolodny","year":"2015","unstructured":"Kolodny E, Fellgiebel A, Hilz MJ, Sims K, Caruso P, Phan TG, et al. Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke. 2015;46:302\u201313.","journal-title":"Stroke"},{"key":"3922_CR91","first-page":"12","volume":"2","author":"MY Soliman","year":"2016","unstructured":"Soliman MY, El-Abassi R, England JD. Diagnosing and treatment of Fabry\u2019s disease from a neurologic perspective. J Rare Dis Res Treat. 2016;2:12\u20138.","journal-title":"J Rare Dis Res Treat"},{"key":"3922_CR92","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.08.010","volume":"23","author":"Q Shi","year":"2014","unstructured":"Shi Q, Chen J, Pongmoragot J, Lanthier S, Saposnik G. Prevalence of Fabry disease in stroke patients\u2013a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2014;23:985\u201392.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"3922_CR93","doi-asserted-by":"crossref","unstructured":"Bots ML, van der Wilk EC, Koudstaal PJ, Hofman A, Grobbee DE. Transient neurological attacks in the general population. Prevalence, risk factors, and clinical relevance. Stroke. 1997;28:768\u201373.","DOI":"10.1161\/01.STR.28.4.768"},{"key":"3922_CR94","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ymgme.2018.08.014","volume":"125","author":"S K\u00f6rver","year":"2018","unstructured":"K\u00f6rver S, Vergouwe M, Hollak CEM, van Schaik IN, Langeveld M. Development and clinical consequences of white matter lesions in Fabry disease: a systematic review. Mol Genet Metab. 2018;125:205\u201316.","journal-title":"Mol Genet Metab"},{"key":"3922_CR95","unstructured":"Centers for Disease Control and Prevention. Cerebrovascular Disease or Stroke: Summary Health Statistics Tables for U.S. Adults: National Health Interview Survey, 2018, Tables A-1a. 2018.https:\/\/ftp.cdc.gov\/pub\/Health_Statistics\/NCHS\/NHIS\/SHS\/2018_SHS_Table_A-1.pdf. Accessed June 2024."},{"key":"3922_CR96","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","volume":"25","author":"AB Fogo","year":"2010","unstructured":"Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F, et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant. 2010;25:2168\u201377.","journal-title":"Nephrol Dial Transplant"},{"key":"3922_CR97","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","volume":"51","author":"C T\u00f8ndel","year":"2008","unstructured":"T\u00f8ndel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008;51:767\u201376.","journal-title":"Am J Kidney Dis"},{"key":"3922_CR98","first-page":"49","volume":"5","author":"O Gheith","year":"2016","unstructured":"Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5:49\u201356.","journal-title":"J Nephropharmacol"},{"key":"3922_CR99","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/pmj.76.899.569","volume":"76","author":"V Mohan","year":"2000","unstructured":"Mohan V, Meera R, Premalatha G, Deepa R, Miranda P, Rema M. Frequency of proteinuria in type 2 diabetes mellitus seen at a diabetes centre in southern India. Postgrad Med J. 2000;76:569\u201373.","journal-title":"Postgrad Med J"},{"key":"3922_CR100","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa0804883","volume":"360","author":"HN Ibrahim","year":"2009","unstructured":"Ibrahim HN, Foley R, Tan L, Rogers T, Bailey RF, Guo H, et al. Long-term consequences of kidney donation. N Engl J Med. 2009;360:459\u201369.","journal-title":"N Engl J Med"},{"key":"3922_CR101","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/00004728-200403000-00002","volume":"28","author":"RB Glass","year":"2004","unstructured":"Glass RB, Astrin KH, Norton KI, Parsons R, Eng CM, Banikazemi M, Desnick RJ. Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes. J Comput Assist Tomogr. 2004;28:158\u201368.","journal-title":"J Comput Assist Tomogr"},{"key":"3922_CR102","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ndt\/gfp554","volume":"25","author":"A Ortiz","year":"2010","unstructured":"Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant. 2010;25:769\u201375.","journal-title":"Nephrol Dial Transplant"},{"key":"3922_CR103","unstructured":"Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2021. 2021.https:\/\/www.cdc.gov\/kidney-disease\/php\/data-research\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/kidneydisease\/publications-resources\/ckd-national-facts.html. Accessed June 2024."},{"key":"3922_CR104","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00467-016-3383-8","volume":"32","author":"GH Neild","year":"2017","unstructured":"Neild GH. Life expectancy with chronic kidney disease: an educational review. Pediatr Nephrol. 2017;32:243\u20138.","journal-title":"Pediatr Nephrol"},{"key":"3922_CR105","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1097\/01.ASN.0000070152.11927.4A","volume":"14","author":"SJ Chadban","year":"2003","unstructured":"Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, Atkins RC. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J Am Soc Nephrol. 2003;14:S131\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"3922_CR106","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1053\/j.ajkd.2018.04.021","volume":"72","author":"SH Saydah","year":"2018","unstructured":"Saydah SH, Xie H, Imperatore G, Burrows NR, Pavkov ME. Trends in Albuminuria and GFR among adolescents in the United States, 1988\u20132014. Am J Kidney Dis. 2018;72:644\u201352.","journal-title":"Am J Kidney Dis"},{"key":"3922_CR107","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12:7\u201311.","journal-title":"Kidney Int Suppl"},{"key":"3922_CR108","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/sj.ki.5002273","volume":"72","author":"PE Stevens","year":"2007","unstructured":"Stevens PE, O\u2019Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007;72:92\u20139.","journal-title":"Kidney Int"},{"key":"3922_CR109","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1055\/s-0036-1584357","volume":"5","author":"N Bugescu","year":"2016","unstructured":"Bugescu N, Naylor PE, Hudson K, Aoki CD, Cordova MJ, Packman W. The psychosocial impact of fabry disease on pediatric patients. J Pediatr Genet. 2016;5:141\u20139.","journal-title":"J Pediatr Genet"},{"key":"3922_CR110","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10545-011-9447-9","volume":"35","author":"MG Bouwman","year":"2012","unstructured":"Bouwman MG, Rombach SM, Schenk E, Sweeb A, Wijburg FA, Hollak CE, Linthorst GE. Prevalence of symptoms in female Fabry disease patients: a case-control survey. J Inherit Metab Dis. 2012;35:891\u20138.","journal-title":"J Inherit Metab Dis"},{"key":"3922_CR111","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1023\/A:1005554103531","volume":"45","author":"RS Sandler","year":"2000","unstructured":"Sandler RS, Stewart WF, Liberman JN, Ricci JA, Zorich NL. Abdominal pain, bloating, and diarrhoea in the United States. Dig Dis Sci. 2000;45:1166\u201371.","journal-title":"Dig Dis Sci"},{"key":"3922_CR112","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1097\/MIB.0b013e31829614c6","volume":"19","author":"MD Coates","year":"2013","unstructured":"Coates MD, Lahoti M, Binion DG, Szigethy EM, Regueiro MD, Bielefeldt K. Abdominal pain in ulcerative colitis. Inflamm Bowel Dis. 2013;19:2207\u201314.","journal-title":"Inflamm Bowel Dis"},{"key":"3922_CR113","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.2147\/JPR.S127014","volume":"10","author":"MD DiBonaventura","year":"2017","unstructured":"DiBonaventura MD, Sadosky A, Concialdi K, Hopps M, Kudel I, Parsons B, et al. The prevalence of probable neuropathic pain in the US: results from a multimodal general-population health survey. J Pain Res. 2017;10:2525\u201338.","journal-title":"J Pain Res"},{"key":"3922_CR114","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1155\/2006\/828964","volume":"11","author":"AL Gibas","year":"2006","unstructured":"Gibas AL, Klatt R, Johnson J, Clarke JT, Katz J. A survey of the pain experienced by males and females with Fabry disease. Pain Res Manag. 2006;11:185\u201392.","journal-title":"Pain Res Manag"},{"key":"3922_CR115","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/01.gim.0000223545.63012.5a","volume":"8","author":"NJ Street","year":"2006","unstructured":"Street NJ, Yi MS, Bailey LA, Hopkin RJ. Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease. Genet Med. 2006;8:346\u201353.","journal-title":"Genet Med"},{"key":"3922_CR116","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10545-017-0095-6","volume":"41","author":"M Arends","year":"2018","unstructured":"Arends M, K\u00f6rver S, Hughes DA, Mehta A, Hollak CEM, Biegstraaten M. Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis. 2018;41:141\u20139.","journal-title":"J Inherit Metab Dis"},{"key":"3922_CR117","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","volume":"26","author":"F Baehner","year":"2003","unstructured":"Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis. 2003;26:617\u201327.","journal-title":"J Inherit Metab Dis"},{"key":"3922_CR118","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/diseases9040072","volume":"9","author":"B Polistena","year":"2021","unstructured":"Polistena B, Rigante D, Sicignano LL, Verrecchia E, Manna R, d\u2019Angela D, Spandonaro F. Survey about the quality of life of Italian patients with Fabry disease. Diseases. 2021;9:72.","journal-title":"Diseases"},{"key":"3922_CR119","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jpain.2007.10.015","volume":"9","author":"A Huguet","year":"2008","unstructured":"Huguet A, Mir\u00f3 J. The severity of chronic pediatric pain: an epidemiological study. J Pain. 2008;9:226\u201336.","journal-title":"J Pain"},{"key":"3922_CR120","unstructured":"Zelaya CE, Dahlhamer JM, Lucas JW, Connor EM. Chronic Pain and High-impact Chronic Pain Among U.S. Adults, 2019. 2020.https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db390-H.pdf. Accessed June 2024."},{"key":"3922_CR121","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41395-018-0256-8","volume":"113","author":"CV Almario","year":"2018","unstructured":"Almario CV, Ballal ML, Chey WD, Nordstrom C, Khanna D, Spiegel BMR. Burden of gastrointestinal symptoms in the United States: results of a Nationally Representative Survey of Over 71,000 Americans. Am J Gastroenterol. 2018;113:1701\u201310.","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 3","key":"3922_CR122","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1007\/s10545-009-9025-6","volume":"33","author":"DA Laney","year":"2010","unstructured":"Laney DA, Gruskin DJ, Fernhoff PM, Cubells JF, Ousley OY, Hipp H, Mehta AJ. Social-adaptive and psychological functioning of patients affected by Fabry disease. J Inherit Metab Dis. 2010;33(Suppl 3):S73-81.","journal-title":"J Inherit Metab Dis"},{"key":"3922_CR123","first-page":"13","volume":"38","author":"N Ali","year":"2018","unstructured":"Ali N, Gillespie S, Laney D. Treatment of depression in adults with Fabry disease. JIMD Rep. 2018;38:13\u201321.","journal-title":"JIMD Rep"},{"key":"3922_CR124","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-020-1307-y","volume":"15","author":"S K\u00f6rver","year":"2020","unstructured":"K\u00f6rver S, Geurtsen GJ, Hollak CEM, van Schaik IN, Longo MGF, Lima MR, et al. Depressive symptoms in Fabry disease: the importance of coping, subjective health perception and pain. Orphanet J Rare Dis. 2020;15:28.","journal-title":"Orphanet J Rare Dis"},{"key":"3922_CR125","unstructured":"National Institute of Mental Health. Major depression. 2023.https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression. Accessed June 2024."},{"key":"3922_CR126","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.3390\/jcm10153367","volume":"10","author":"N Ali","year":"2021","unstructured":"Ali N, Caceres A, Hall EW, Laney D. Attention deficits and ADHD symptoms in adults with Fabry disease-a pilot investigation. J Clin Med. 2021;10:3367.","journal-title":"J Clin Med"},{"key":"3922_CR127","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000226792","volume":"1","author":"T Duning","year":"2009","unstructured":"Duning T, Deppe M, Keller S, Schiffbauer H, Stypmann J, B\u00f6ntert M, et al. Excessive daytime sleepiness is a common symptom in Fabry disease. Case Rep Neurol. 2009;1:33\u201340.","journal-title":"Case Rep Neurol"},{"key":"3922_CR128","first-page":"56","volume":"62","author":"HK Pihlstr\u00f8m","year":"2021","unstructured":"Pihlstr\u00f8m HK, Weedon-Fekj\u00e6r MS, Bjerkely BL, von der Lippe C, \u00d8rstavik K, Mathisen P, et al. Health-related quality of life in Norwegian adults with Fabry disease: Disease severity, pain, fatigue and psychological distress. JIMD Rep. 2021;62:56\u201369.","journal-title":"JIMD Rep"},{"key":"3922_CR129","first-page":"85","volume":"37","author":"DA Laney","year":"2017","unstructured":"Laney DA, Clarke V, Foley A, Hall EW, Gillespie SE, Holida M, et al. The impact of Fabry disease on reproductive fitness. JIMD Rep. 2017;37:85\u201397.","journal-title":"JIMD Rep"},{"key":"3922_CR130","first-page":"57","volume":"21","author":"A Holmes","year":"2015","unstructured":"Holmes A, Laney D. A retrospective survey studying the impact of Fabry disease on pregnancy. JIMD Rep. 2015;21:57\u201363.","journal-title":"JIMD Rep"},{"key":"3922_CR131","doi-asserted-by":"crossref","unstructured":"Mersebach H, Johansson JO, Rasmussen AK, Bengtsson BA, Rosenberg K, Hasholt L, et al. Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. Genet Med 2007;9:812\u20138.","DOI":"10.1097\/GIM.0b013e31815cb197"},{"key":"3922_CR132","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/humupd\/dml028","volume":"12","author":"The ESHRE Capri Workshop Group","year":"2006","unstructured":"The ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum Reprod Update. 2006;12:483\u201397.","journal-title":"Hum Reprod Update"},{"key":"3922_CR133","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1089\/thy.2018.0416","volume":"29","author":"AR Cappola","year":"2019","unstructured":"Cappola AR, Desai AS, Medici M, Cooper LS, Egan D, Sopko G, et al. Thyroid and cardiovascular disease: research agenda for enhancing knowledge, prevention, and treatment. Thyroid. 2019;29:760\u201377.","journal-title":"Thyroid"},{"key":"3922_CR134","unstructured":"American Thyroid Association. General Information\/Press Room. https:\/\/www.thyroid.org\/media-main\/press-room\/. Accessed June 2024."},{"key":"3922_CR135","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1210\/jcem.87.3.8302","volume":"87","author":"B Biondi","year":"2002","unstructured":"Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of thyroid hormone on cardiac function - the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab. 2002;87:968\u201374.","journal-title":"J Clin Endocrinol Metab"},{"key":"3922_CR136","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/S2468-2667(19)30155-0","volume":"4","author":"D Zhu","year":"2019","unstructured":"Zhu D, Chung HF, Dobson AJ, Pandeya N, Giles GG, Bruinsma F, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health. 2019;4:e553\u201364.","journal-title":"Lancet Public Health"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03922-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03922-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03922-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T02:55:15Z","timestamp":1757386515000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03922-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":136,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3922"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03922-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RJH is a member of the Fabry Registry Advisory Board and the FollowMe registry, consults with Sanofi and Amicus Therapeutics, Chiesi Farmaceutici and Freeline, and has been an investigator in clinical trials sponsored by Amicus Therapeutics, Idorsia, Protalix Biotherapeutics, Sangamo Therapeutics, Sanofi, and Takeda. These activities have been monitored and found to be in compliance with the conflict of interest policies at Cincinnati Children\u2019s Hospital Medical Center. DL is chair of the North American Fabry Registry Board, consults and\/or has been an investigator and coordinator in clinical trials sponsored by 4DMT, Amicus Therapeutics, Chiesi Farmaceutici, Protalix BioTherapeutics, Sangamo, Sanofi-Genzyme, Spark Therapeutics, and Takeda-Shire. These activities have been monitored and found to be in compliance with the conflict of interest policies at the Emory University School of Medicine. AW and SK are employees and shareholders of Sanofi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Some data within the manuscript were presented at the 18th Annual WORLD Symposium hybrid (virtual and in-person) congress, February 7\u201311, 2022.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of prior presentation"}}],"article-number":"433"}}